FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]
From General Health Awareness to Occupational Exposure Concerns
For decades, general health and science information has served as the foundation for public understanding of medication risks and benefits. This broad educational heritage has empowered individuals to make informed decisions about their healthcare, particularly regarding prescription drugs and their potential long-term effects. Within this context, the transition from general health awareness to specific occupational exposure concerns represents a natural evolution in how we evaluate pharmaceutical risk. The shift becomes particularly relevant when considering the widespread use of metoclopramide, commonly known by the brand name Reglan, which has been prescribed for various gastrointestinal conditions. As general health education has matured, attention has increasingly focused on the duration and intensity of medication exposure as critical factors in risk assessment. This perspective naturally extends to occupational settings where healthcare professionals, pharmacy workers, and others may encounter repeated or prolonged exposure scenarios. From this foundation of general health literacy, we now turn to the specific question of how exposure patterns in professional environments may influence the valuation of claims related to medication use. The occupational dimension introduces additional considerations regarding monitoring protocols, documentation practices, and the cumulative nature of exposure that differ from typical patient-consumer contexts. Understanding these occupational exposure concerns is essential for a comprehensive evaluation of claim factors.
Reglan and Tardive Dyskinesia: Medical Evidence and Risk Factors
Reglan (metoclopramide) is associated with a risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also notes that Reglan is contraindicated in patients with a history of TD, and that treatment should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks; for diabetic gastroparesis, total treatment duration should also not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD includes involuntary, repetitive movements of the face, tongue, trunk, or extremities, which may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanism linking metoclopramide to TD involves dopamine receptor blockade in the basal ganglia, similar to antipsychotic drugs. Metoclopramide is a dopamine D2 receptor antagonist, and chronic blockade can lead to upregulation of dopamine receptors, resulting in abnormal involuntary movements. The prescribing information also warns that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Epidemiological Evidence and Risk Stratification
Epidemiological data on the incidence of metoclopramide-induced TD have varied. A real-world epidemiology study using the MarketScan Research database (2011-2020) analyzed TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess TD risk based on more recent data, as older studies reported inconsistent incidence estimates ranging from 1% to 15% (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another review of the literature, including PubMed and Google Scholar searches, concluded that the risk of TD from metoclopramide is low, in the range of 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). This review identified high-risk groups as elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). From a risk perspective, the adequacy of warnings regarding Reglan and TD has been a subject of regulatory and legal scrutiny. The boxed warning explicitly states the risk, contraindications, and duration limits, but historical prescribing practices may have involved longer-term use without adequate monitoring.
Claim Valuation Factors for Reglan TD Settlements
For settlement considerations, claim valuation factors include the severity and irreversibility of TD, the duration of Reglan exposure, the presence of risk factors (e.g., age, diabetes, renal impairment), and the timeline between exposure and documented harm. The timeline is critical: TD may develop after months or years of use, and symptoms can persist or become permanent even after discontinuation. The prescribing information advises immediate discontinuation if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because metoclopramide can mask TD, diagnosis may be delayed, complicating the causal link. In summary, Reglan (metoclopramide) carries a known risk of tardive dyskinesia, with incidence estimates varying but generally considered low in recent studies. Risk factors include longer treatment duration, higher cumulative dose, older age, female sex, diabetes, renal or hepatic impairment, and concurrent use of antipsychotics. The FDA boxed warning mandates short-term use and monitoring, but historical non-adherence to these guidelines has led to litigation. Settlement valuation depends on individual patient factors, including the severity of TD, duration of exposure, and timing of diagnosis relative to treatment.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Reglan and tardive dyskinesia?
Reglan (metoclopramide) is a dopamine D2 receptor antagonist used for gastrointestinal conditions. Chronic use can lead to dopamine receptor upregulation in the basal ganglia, causing tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA boxed warning states that risk increases with duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
What factors affect the valuation of a Reglan TD claim?
Key valuation factors include severity and irreversibility of TD, duration of Reglan exposure, presence of risk factors (age, diabetes, renal impairment), and timeline between exposure and diagnosis. Delayed diagnosis due to masking of symptoms can complicate causation. Each claim is evaluated individually based on medical records and exposure history.
What are the risk factors for developing TD from Reglan?
Risk factors include longer treatment duration, higher cumulative dose, older age, female sex, diabetes, renal or hepatic impairment, and concurrent use of antipsychotics. High-risk groups are elderly females, diabetics, and those with liver/kidney failure (https://pubmed.ncbi.nlm.nih.gov/31050085/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.